-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Enterprise News] On August 19, many pharmaceutical companies such as Kangzhong Medical, Joincare, Nanwei Medicine, Tebao Bio, Tibet Pharmaceutical, Zejing Pharmaceutical, and Guangji Pharmaceutical disclosed their performance reports for the first half of 2022 , Among them, Tebao Bio, a pharmaceutical company, achieved double growth in revenue and net profit in the first half of the year
.
According to the announcement of Tebao Biology, the company achieved operating income of 715 million yuan in the first half of the year, a year-on-year increase of 52.
35%; net profit was 134 million yuan, a year-on-year increase of 86.
36%
.
Regarding the reasons for the increase in revenue, the company stated that the main reason is: with the continuous accumulation of scientific evidence for clinical cure of chronic hepatitis B and the improvement of the level of cognition, the market penetration rate of the company's product Pegabine continues to increase, and the sales revenue continues to maintain a growth trend
.
The increase in net profit was due to the continuous improvement of management quality and efficiency while the company's operating income increased, and the overall expense ratio showed a downward trend, which led to an increase in profits
.
In addition, benefit from the company's net profit growth
.
During the reporting period, the company's basic earnings per share increased by 83.
33% year-on-year, and the basic earnings per share after deducting non-recurring gains and losses increased by 68.
18% year-on-year
.
According to the semi-annual report, Tebao Bio is an innovative biopharmaceutical enterprise mainly engaged in the research and development, production and sales of recombinant proteins and their long-acting modified drugs
.
The company takes immune-related cytokine drugs as the main research and development direction, and is committed to providing better solutions for the treatment of major diseases such as viral hepatitis and malignant tumors
.
As an innovative biopharmaceutical enterprise, the company attaches great importance to research and development.
Based on the development trend of recombinant protein drug characteristics, life cycle management and regulatory requirements, the company has built a complete innovative drug research and development system, covering drug technology development, quality control, druggability research, The whole process of preclinical and clinical research, product industrialization and scale-up
.
In specific research and development activities, the core technology platform is used as the support, and innovative drugs are developed in a project management mode; at the same time, the company continues to pay attention to the development of new targets and new mechanism drugs, continuously enrich the company's product line, and continuously enhance its core competitiveness
.
During the reporting period, the company's research and development achievements have been considerable, and the research and development progress of many projects has accelerated.
Among them, the "Y-type polyethylene glycol recombinant human granulocyte-stimulating factor (YPEG-G-CSF)" project has progressed rapidly and has completed Phase III clinical trials.
Research, is applying for drug registration
.
The company also has a number of projects in the phase II clinical research stage, including the first confirmatory clinical trial of long-acting interferon with hepatitis B surface antigen clearance (clinical cure) as the main efficacy indicator - chronic hepatitis B clinical cure research project, "Y "Y-type polyethylene glycol recombinant human growth hormone (YPEG-GH)" project, "Y-type polyethylene glycol recombinant human erythropoietin (YPEG-EPO)" project,
etc.
In addition, ACT50 is conducting pharmacy and preclinical studies (carrying out preclinical toxicology studies), and ACT60 and AK0706 projects are conducting pharmacy and preclinical studies
.
At present, the company's existing products are divided into infection line and blood tumor line.
Among them: Infection line product Pegabin was approved for marketing in 2016.
It is the first long-acting interferon product with completely independent intellectual property rights in China.
It is mainly used in virus field of hepatitis
.
In the blood tumor line, the products Telli, Telzin, and Telcon are currently the national medical insurance category B drugs.
As the clinical guidelines for whitening, the first radiotherapy and chemotherapy whitening drugs are recommended, and the market is expected to continue to grow
.
Affected by the good results, the stock price of Tebao Bio rose on August 18.
As of 10:57, the stock rose 3.
43%, with a quotation of 28.
38 yuan, a turnover of 129 million, and a turnover rate of 2.
00%
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
According to the announcement of Tebao Biology, the company achieved operating income of 715 million yuan in the first half of the year, a year-on-year increase of 52.
35%; net profit was 134 million yuan, a year-on-year increase of 86.
36%
.
Regarding the reasons for the increase in revenue, the company stated that the main reason is: with the continuous accumulation of scientific evidence for clinical cure of chronic hepatitis B and the improvement of the level of cognition, the market penetration rate of the company's product Pegabine continues to increase, and the sales revenue continues to maintain a growth trend
.
The increase in net profit was due to the continuous improvement of management quality and efficiency while the company's operating income increased, and the overall expense ratio showed a downward trend, which led to an increase in profits
.
In addition, benefit from the company's net profit growth
.
During the reporting period, the company's basic earnings per share increased by 83.
33% year-on-year, and the basic earnings per share after deducting non-recurring gains and losses increased by 68.
18% year-on-year
.
According to the semi-annual report, Tebao Bio is an innovative biopharmaceutical enterprise mainly engaged in the research and development, production and sales of recombinant proteins and their long-acting modified drugs
.
The company takes immune-related cytokine drugs as the main research and development direction, and is committed to providing better solutions for the treatment of major diseases such as viral hepatitis and malignant tumors
.
As an innovative biopharmaceutical enterprise, the company attaches great importance to research and development.
Based on the development trend of recombinant protein drug characteristics, life cycle management and regulatory requirements, the company has built a complete innovative drug research and development system, covering drug technology development, quality control, druggability research, The whole process of preclinical and clinical research, product industrialization and scale-up
.
In specific research and development activities, the core technology platform is used as the support, and innovative drugs are developed in a project management mode; at the same time, the company continues to pay attention to the development of new targets and new mechanism drugs, continuously enrich the company's product line, and continuously enhance its core competitiveness
.
During the reporting period, the company's research and development achievements have been considerable, and the research and development progress of many projects has accelerated.
Among them, the "Y-type polyethylene glycol recombinant human granulocyte-stimulating factor (YPEG-G-CSF)" project has progressed rapidly and has completed Phase III clinical trials.
Research, is applying for drug registration
.
The company also has a number of projects in the phase II clinical research stage, including the first confirmatory clinical trial of long-acting interferon with hepatitis B surface antigen clearance (clinical cure) as the main efficacy indicator - chronic hepatitis B clinical cure research project, "Y "Y-type polyethylene glycol recombinant human growth hormone (YPEG-GH)" project, "Y-type polyethylene glycol recombinant human erythropoietin (YPEG-EPO)" project,
etc.
In addition, ACT50 is conducting pharmacy and preclinical studies (carrying out preclinical toxicology studies), and ACT60 and AK0706 projects are conducting pharmacy and preclinical studies
.
At present, the company's existing products are divided into infection line and blood tumor line.
Among them: Infection line product Pegabin was approved for marketing in 2016.
It is the first long-acting interferon product with completely independent intellectual property rights in China.
It is mainly used in virus field of hepatitis
.
In the blood tumor line, the products Telli, Telzin, and Telcon are currently the national medical insurance category B drugs.
As the clinical guidelines for whitening, the first radiotherapy and chemotherapy whitening drugs are recommended, and the market is expected to continue to grow
.
Affected by the good results, the stock price of Tebao Bio rose on August 18.
As of 10:57, the stock rose 3.
43%, with a quotation of 28.
38 yuan, a turnover of 129 million, and a turnover rate of 2.
00%
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
